secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001437749-24-025872
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics Q2 2024 net loss $2.7M; AJ201 trial topline data expected H2 2024
--------------------------------------------------------------------------------

- Cash and equivalents $4.9M at June 30, 2024, up from $1.8M at Dec 31, 2023.
- Net loss $2.7M ($6.43/share) for Q2 2024, compared to $4.0M ($38.74/share) in Q2 2023.
- AJ201 Phase 1b/2a SBMA trial last patient visit complete; topline data expected in H2 2024.
- Raised $4.4M gross proceeds from April 2024 warrant exercise; 1-for-75 reverse stock split effected.
- Regained Nasdaq compliance in May 2024 after reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000143774924025872/0001437749-24-025872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000143774924025872/atxi20240520_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer